Mpex pockets $32M in second venture round

San Diego-based Mpex Pharmaceuticals has raised $32 million in its second round of venture capital. The round was led by SV Life Sciences. The biotech's most advanced candidate is an aerosol antibacterial being developed to treat patients with cystic fibrosis and those with other serious respiratory infections. "This capital will enable us to advance our first two candidates through preclinical and early clinical development, as well as attract and support future R&D partnerships," said Mpex President and CEO Bill Gerhart.

- read this press release for more

ALSO: Germany's Avontec has raised $18 million in its second round. Release

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.